

Vivimed announces acquisition of SONEAS by Group's API business, UQUIFA**SONEAS broadens UQUIFA's offering in the CDMO sector with New Development capabilities and, an enhanced Project Pipeline**

Hyderabad, India, May 10, 2018- Vivimed Labs Spain S.L, the parent of UQUIFA S.A, has signed definitive agreements to facilitate the acquisition of SONEAS, a Budapest (Hungary) headquartered CDMO company, focussed on the Innovator Pharmaceutical and Fine Chemical sectors. The business has been acquired from Lochlomond and Euroventures which are both based out of Hungary. SONEAS has for the year 2017, reported revenues of €12.2mn.

The acquisition broadens UQUIFA's market offering in the CDMO space by enhancing its ability to now undertake preclinical, phase I, II and III NCE project development. These projects can then also potentially feed into UQUIFA's existing cGMP inspected and approved manufacturing facilities in Spain and Mexico, creating a high-value project pipeline.

In terms of technology, SONEAS brings a high level of competency in NCE development as well as new technologies such as metathesis reactions and heterocyclic chemistry to the UQUIFA technology tool box. From a manufacturing perspective, SONEAS brings both cGMP pilot plant and over 180KL of key starting material (KSM) capacities to the UQUIFA portfolio. It also counts within its pipeline three customer projects which are in Phase 2a/2b and one in Phase 3 of the NCE development lifecycle.

UQUIFA believes the acquisition of SONEAS will allow it to expand faster into the CDMO sector (40% of UQUIFA sales) where it already has an important presence in the geographies of USA, Europe and Japan. To build on the cost-effective development capabilities with aggressive timelines and, to deliver effective results for the combined customer base, will be a key objective for UQUIFA, according to Mr Saurabh Gurnurkar, the Executive Director.

About UQUIFA:

UQUIFA, has three US FDA inspected manufacturing sites across Spain and Mexico and, caters to the Generic API and CDMO API segments of the global pharmaceutical market. It has customer relationships with leading innovator and generic formulation companies and, has been a trusted franchise across regulated markets, for 80 years of its existence. Gilead Lifesciences, GSK, Mylan, Esteve Quimica, Apotex, Medinsa, and Actavis are some of the key customers of UQUIFA.

UQUIFA is the API business of Vivimed Labs Limited, a Pharmaceuticals and Specialty Chemicals company headquartered in Hyderabad, India. It has recently raised capital from **OrbiMed**, which is a leading healthcare investment firm, with over \$14 billion in assets under management.

For further information on UQUIFA, visit www.uquifa.com

About SONEAS:

SONEAS, established in 1996, with a team strength of 177 people, is a Budapest, Hungary headquartered firm with business verticals focused on R+D and CMO, targeted at the Innovator Pharma and Fine Chemical sectors.

In R+D, it is a professional chemical service provider with research and analytical labs across three operating sites in Budapest. It also has an 8,000 m² facility which houses process R+D, kilo lab and a cGMP approved pilot plant which was commissioned in 2002. In CMO, it is operating on 85,000 m² site and capable of providing starting materials, intermediates for pharma and non-pharma applications as well as other fine chemical products on a commercial scale. SONEAS has a well-diversified customer base including European, USA and Japanese clients from small biotech to large international companies.

For further information on SONEAS, visit www.soneas.com

*** **

Analyst and Investor Enquiries

Sunil Arab
B. Rajaprasad
Vivimed Labs Limited

+91 40 2717 6005
Sunil.arab@vivimedlabs.com
rajaprasad.b@vivimedlabs.com

For further information on Vivimed, visit www.vivimedlabs.com

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.